Showing 1621-1630 of 6809 results for "".
Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseLaser and Energy Devices Session: Dr. Ross
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/laser-and-energy-devices-session-dr-ross/32682/E. Vic Ross, MD, discusses some of the basics and applications that he covered during "Lasers and Energy Devices Used to Treat Medical Problems: What's New in 2025" at Maui Derm 2025.Journal Club: Updated Clinical Practice Guidelines
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-updated-clinical-practice-guidelines/32316/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with new Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, about the updated clinical practice guidelines for atopic dermatitis published in the Journal of Dermatology in December.Saeki H, et alDermwireTV 2024 Year in Review
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisPearls for Treating Atopic Skin
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-for-treating-atopic-skin/29483/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with dermatologist James Del Rosso, DO, about different ways to treat patients with atopic dermatitis (AD), including using a well-made moisturizers, and also exploring both the science and the use of newer topical agents. ThisTalking to Patients About Starting a JAK Inhibitor in Atopic Dermatitis
https://practicaldermatology.com/series/pa-perspectives/talking-patients-about-starting-jak-inhibitor-atopic-dermatitis/26919/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses the importance of offering patients quick access to medication, and tips on how to best discuss safety.SCALE 2024: Dr. Linda Stein Gold on What’s New and What’s Coming in AD
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-linda-stein-gold-on-whats-new-and-whats-coming-in-ad/26412/Linda Stein Gold, MD, discusses new topical, oral, and biologic drugs for the treatment of atopic dermatitis at Music City SCALE.Sensus Healthcare: What's Next
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-next/19947/Along with other healthcare companies, Sensus faced challenges in 2020 as the COVID-19 pandemic emerged. But CEO Joe Sardano says the company is poised for success in 2021 and beyond. He discusses efforts to optimize physician reimbursement and strategies to expand access for patients.Sensus Healthcare: What's New
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-new/19946/Adding to its flagship SRT-100 device for superficial radiation therapy, Sensus has launched the Sculptura® Radiotherapy Oncology System and is poised to bring new aesthetic devices to market. Sensus CEO Joe Sardano says that as it grows, the company remains focused on relationships with its clientsAlmost There: Toward Systemic Therapy for AD in Children
https://practicaldermatology.com/topics/atopic-dermatitis/almost-there-toward-systemic-therapy-for-ad-in-children/19934/With the approval of the first biologic for management of atopic dermatitis, a new era is underway, says Amy Paller, MD. She addresses the role of dupilumab in practice and provides a look ahead at other agents in the pipeline for adolescent and pediatric patients.